Floatz logo

Dostarlimab

Stage III (Any T, N+)

Memorial Sloan Kettering Cancer Centermonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Stage III (Any T, N+) cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Memorial Sloan Kettering Cancer Center
Phase 2CCC
Capecitabine
Memorial Sloan Kettering Cancer Center
Phase 2CCC

Same molecule, other indications

Dostarlimab is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
68 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
65 / 100
View asset →
Neoplasms, ColonDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →